U.S. Withdraws from WHO: Impact on Global Health Security and Relations

By João L. Carapinha

January 21, 2025

President Trump has signed an executive order to begin the U.S. withdraws from WHO. The order cites the organization’s mishandling of the COVID-19 pandemic. It also highlights the WHO’s failure to implement necessary reforms and its lack of independence from political influence. Additionally, the order addresses the disproportionate financial contributions required from the U.S. compared to other countries. This move involves stopping U.S. funding and personnel support for the WHO. It also seeks alternative international partners.

The U.S. withdrawal from the WHO is driven by criticisms of its handling of the COVID-19 pandemic and other global health crises. The WHO faces accusations of failing to implement urgent reforms. It is also criticized for being unduly influenced by member states’ politics. The executive order emphasizes disparities in financial contributions. The U.S. contributes significantly more than countries like China, despite China’s larger population. The order revokes previous notifications and orders concerning U.S. involvement with the WHO. It directs government departments to stop funding and recall personnel while seeking new partners.

Background

The U.S. withdraws from WHO is not unprecedented. It was first initiated in 2020 but later retracted. The WHO has faced harsh criticism for its response to the COVID-19 pandemic, a major global health crisis. Health experts warn that this withdrawal could weaken global defenses against infectious diseases and pandemics. It may undo decades of progress in fighting diseases like AIDS, malaria, and tuberculosis.

The U.S. withdrawal from the WHO may compromise global health security. It could diminish U.S. influence and financial support essential for international health initiatives and pandemic preparedness. Stopping U.S. funding could severely affect the WHO’s ability to run global health programs. This might result in gaps in health services and research. The U.S. will need to forge new partnerships to continue supporting global health initiatives. This transition could create instability in global health governance. The withdrawal might also disrupt collaborative research efforts and the sharing of health data, which are critical for developing effective health policies.

Overall, the implications of the U.S. withdrawal from the WHO are extensive. They may have significant consequences for global health security, research, and outcomes.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.